Cadence Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cadence Bank’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,671	Closed	-$237K	–	223
2019 Q1	$237K	Hold	2,671	–	–	0.02%	212
2018 Q4	$227K	Hold	2,671	–	–	0.03%	208
2018 Q3	$259K	Sell	2,671 -26	-1%	-$2.6K	0.02%	212
2018 Q2	$254K	Hold	2,697	–	–	0.02%	211
2018 Q1	$219K	Hold	2,697	–	–	0.02%	229
2017 Q4	$240K	Buy	+2,697	New	+$235K	0.02%	222

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cadence Bank's BMRN Position: Q2 2019 in Review

Cadence Bank sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2019, closing a stake of 2,671 shares — an estimated $237K sold.

Cadence Bank first reported a position in BMRN in Q4 2017 and held it in 6 quarters. The position peaked at $259K in Q3 2018. 482 funds tracked by Wall St. Rank hold BMRN as of Q2 2019.

Cadence Bank reported no remaining BioMarin Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Cadence Bank sold 2,671 BioMarin Pharmaceuticals shares in Q2 2019, an estimated $237K.
Cadence Bank first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 6 quarters.
Cadence Bank's BioMarin Pharmaceuticals position peaked at $259K in Q3 2018.
482 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2019.

Based on Cadence Bank's 13F filing for Q2 2019, filed 30 Jul 2019.